in mood disorders and schizophrenia respectively. These results raise the possibility that inflammatory mediators may contribute to the biology of psychiatric disorders.
The term dysthymia has been sometimes used in referring to all those unplesant states with depressive, anxious or obsessional features leading to mild, chronic depression. Despite the formal recognition of dysthymia as a subtype of affective or mood disorder in both ICD 10 and DSM IV, two questions have been raised about the validity of such a concept. The first question is the following: Is dysthymia a personality disorder? The other question is on the clinical and biological differentiation between dysthymia and major depression. The paper from Anisman et al in this issue 1 suggests a role for cytokines in the pathophysiology of dysthymia; additionally, it confirms the different patterns of hypothalamic-pituitary-adrenal (HPA) axis regulation in melancholic and atypical depression. Although no conclusive answers can be given at this point, neuroendocrine-immune interactions are an important biological substrate in mood disorders. However, the heterogeneous nature of the clinical subtypes of affective disorders has led to methodological difficulties and sometimes inconsistent approaches. During the past years many studies have examined the immune system in depression. [2] [3] [4] [5] Moreover, the immune and the neuroendocrine networks interface each other via receptors and informational molecules that are shared by both systems. Hormones and neurotransmitters influence the immune response in vivo and in vitro; on the other hand, peripherally generated immune mediators (ie cytokines) signal the brain and activate neuroendocrine circuits. 3, 6 The HPA axis has been the focus of extensive research because of its important role in maintaining physiological homeostasis under both basal and challenge conditions. 7 Excessive HPA responsivity to stressors during human life may contribute to cause the medical consequences of depression, such as decreased bone mineral density, hippocampal atrophy, and cardiovascular illness. 5, 8, 9 Those medical conse- The few available studies on dysthymia show that, contrary to major depression, the endocrine or immune findings are much more subtle in dysthymia than they are in major depression. Alterations in the dexamethasone suppression test (DST) are less common in dysthymia 10 and cortisol responses to oCRH have been found to be higher in depression than in dysthymia. 11 Interestingly, patients with Cushing's syndrome have low CSF CRH levels and present with chronic depression, of the atypical subtype, which shares many clinical features with dysthymia. 12 The role of interleukins either in the activation of the HPA axis or in the response to chronic stress has been studied by several groups worldwide. First of all, interleukins, such as IL-1 and IL-2, are potent stimulators of corticotropinreleasing hormone (CRH) secretion, while CRH itself can modulate cytokine release. 13 However, abnormalities in cytokine levels have not been consistently found in all studies of patients with mood disorders. A pattern that seems to emerge from available studies is that altered patterns of cytokines are more likely to be encountered in chronic disorders, such as chronic fatigue syndrome 14 or, as Anisman et al show in this issue, 1 dysthymia. In this regard, it is noteworthy that Anisman et al found that IL-1␤ was more dysregulated in depression than in dysthymia, regardless of typical or atypical symptoms. Dysregulation or peripheral IL-1␤ may impact on specific brain circuitries. IL-1␤ is known to regulate hypothalamic-pituitary function in infection, and inflammation. Peripheral IL-1␤ secretion leads to production of IL-1␤ within the brain and induction of nitric oxide synthase type 2 (iNOS), resulting in the release of nitric oxide (NO). NO diffuses into CRH-secreting neurons and may tonically inhibit hypothalamic CRH production. 
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− subset, that are spontaneously cytotoxic against susceptible targets as tumor-transformed or virus-infected cells. 16 NK cell activity is sensitive both in vivo and in vitro to cyto-kines and HPA axis hormones. Glucocorticoids are potent in vitro negative modulators of human NK cell activity, which is also modulated by at least two proopiomelanocortin (POMC)-derived peptides, ACTH and beta-endorphin. 17 Thus, immunosuppressive effects of glucocorticoids may be couterbalanced by POMC-derived peptides. Inverse relations between spontaneous NK cell activity and severity of symptoms have already been described in major depression, 18, 19 although no distinction between typical and atypical features has ever been considered. Disturbances of NK cell activity in humans may be a secondary effect of stress perception, as the authors suggest in this issue. However, Angeli et al did not find gross abnormalities of spontaneous NK cell activity either in subjects with anorexia nervosa 20 or in patients with Cushing's syndrome, 21 while subjects at the early onset of Alzheimer's disease showed enhanced levels of NK activity, in comparison to an age-and sex-matched control group, that were very similar to those from a group of younger normal volunteers (Prolo et al, unpublished data).
Neuroendocrine systems show either a circadian organization or one dependent on the restactivity/sleep-wake cycle. Immune effectors appear to be regulated in the same way. 22 These temporal organizations might have functional implications. For instance, ACTH and cortisol levels correlate directly with the active period both in diurnal and nocturnal animals, indicating that higher levels of adrenal corticosteroids are necessary for the awake state. In contract, cerebrospinal fluid levels of CRH present diurnal variations, with higher levels in the evening and lowest levels early in the morning, that are the opposite of plasma cortisol levels, which show a peak around 08:00 am and a nadir around 10:00 pm. 23 Unfortunately, most studies have considered only a few time points, usually in the morning. In order to fully understand human neuroendocrine function, detailed studies are required with as many evaluation points as possible, under rigorous study conditions. 24 After data are collected it is crucial to not only examine plasma hormone concentrations and (through the use of deconvolution methods) secretion rates, but also to assess sequence-dependent patterns, by assessment of parameters such as approximate entropy (ApEn). ApEn is a scale and translation-invariant and model-independent regularity statistics developed to quanitfy the orderliness of sequential measures 25 such as hormonal time series. Given the results from the studies conducted so far, it is likely that future studies using frequent sampling, and sequence-dependent measures will further characterize subtle dysregulations of neuroendocrine-immune interactions in dysthymia.
One important point to be resolved on the possible role of inflammatory mediators in psychiatric disorders is the specificity of these findings. This issue of Molecular Psychiatry features an article by Katila et al 26 on interleukin-1 gene polymorphisms in schizophrenia. That study shows that the frequencies of the IL-1␣ (a base exchange at the position −889) allele 2, IL-1␤ (a base exchange at the position −511) allele 1, and IL-1 receptor antagonist allele 1 tended to be somewhat higher in the schizophrenia group; the number of carriers of this haplotype as well as the haplotype frequency were significantly higher in the patient group. Moreover, the effect seems to require homozygosity, as the number of homozygotes of this haplotype was significantly higher in schizophrenic patients. These results suggest that the cytokine alterations might be genetically determined in psychiatric disorders. Further studies should examine IL-1 system genes in other psychiatric disorders, such as mood disorders, to determine whether the genetic findings of Katila et al are specific to schizophrenia.
